SCHEMBL223594

SCHEMBL223594

O=[N+]([O-])c1ccc(SSc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPT P10636 2/20 0.59
HSP90AA1 P07900 1/20 0.56
ALDH1A1 P00352 5/20 0.54
HSD17B10 Q99714 2/20 0.54
ACHE P22303 1/20 0.54
LMNA P02545 1/20 0.52
CES1 P23141 1/20 0.50
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
LOXL2 Q9Y4K0 1/20 0.48
CA12 O43570 1/20 0.48
CA3 P07451 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA5A P35218 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL943255 0.93 MAPT (0.53) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL8729226 0.91 ALDH1A1 (0.62) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL5026213 0.89 ACHE (0.75) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL8531165 0.89 ACHE (0.75) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL11856128 0.89 KMT2A (0.78) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL945833 0.87 HSPB1 (0.63) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL4908007 0.86 HSD17B10 (0.52) MEN1KMT2AMAPTHSP90AA1ALDH1A1
SCHEMBL3328543 0.84 MAPT (0.79) MEN1KMT2AMAPTALDH1A1HSD17B10
SCHEMBL4163474 0.84 MAPT (0.79) MEN1KMT2AMAPTALDH1A1HSD17B10
SCHEMBL22567 0.83 ALDH1A1 (0.72) MEN1KMT2AALDH1A1HSD17B10ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 898 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163101-A1 METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE Research & Business Foundation Sungkyunkwan University (KR) 2025-05-22 US claimed
CN-119751366-A Dual-mechanism deep fungal infection resistant medicament 上海友长医药有限公司 2025-04-04 CN claimed
CN-119431313-A Antifungal compound, preparation method and application thereof 上海交通大学 2025-02-14 CN claimed
CN-119263422-B Sterilizing nanotube material for wastewater treatment 温州医科大学附属第一医院 2025-02-11 CN claimed
EP-4488290-A1 METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE ABTIS Co., Ltd. (KR) 2025-01-08 EP claimed
WO-2023167564-A1 METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE 앱티스 주식회사 2023-09-07 WO claimed
CN-115926022-A Isomerized eucommia ulmoides elastomer and preparation method and application thereof 北京化工大学 2023-04-07 CN claimed
CN-114042155-B Multifunctional drug carrier material based on gold nanocages and preparation method thereof 浙江大学(CN) 2023-01-13 CN claimed
CN-114042155-A Multifunctional drug carrier material based on gold nanocages and preparation method thereof 浙江大学 2022-02-15 CN claimed
CN-107011253-B Method for producing charged crosslinkers 伊缪诺金公司 2021-01-15 CN claimed
EP-1015402-B1 Method for producing compounds containing fluorine, in particular fluorobenzaldehydes and fluorobenzonitriles CLARIANT GMBH (DE) 2002-12-04 EP claimed
US-6166242-A Method for producing compounds containing fluorine, in particular fluorobenzaldhydes and fluorobenzonitriles AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) 2000-12-26 US claimed
US-6001555-A DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-12-14 US claimed
EP-0756611-B1 PREPARATION PROCESS FOR POLYMER-MODIFIED BITUMEN SHELL INT RESEARCH (NL) 1998-03-04 EP claimed
EP-0782632-A1 A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) 1997-07-09 EP claimed
WO-1996009406-A9 A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN 1996-05-23 WO claimed
US-5514770-A Sulfides of nitroamino triphenyl and substitution or amino functionalized products thereof and the method of preparing the same ANSONG OMARI (US) 1996-05-07 US claimed
WO-1996009406-A1 A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-03-28 WO claimed
EP-0693056-A1 PROCESS FOR THE PREPARATION OF ARYL- AND HETEROARYLSULPHURPENTAFLUORIDES ZENECA LIMITED (GB) 1996-01-24 EP claimed
WO-1994022817-A1 PROCESS FOR THE PREPARATION OF ARYL- AND HETEROARYLSULPHURPENTAFLUORIDES ZENECA LIMITED (GB) 1994-10-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163101-A1 METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE TST, DHFR, FCGRT MEN1 4515/4885KMT2A 3073/4885MAPT 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.